Pegfilgrastim
- Generic Name
- Pegfilgrastim
- Brand Names
- Fulphila, Fylnetra, Neulasta, Udenyca, Ziextenzo, Cegfila (previously Pegfilgrastim Mundipharma), Nyvepria, Pelgraz, Grasustek, Pelmeg, Stimufend
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 208265-92-3
- Unique Ingredient Identifier
- 3A58010674
- Background
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of de...
- Indication
Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
...
- Associated Conditions
- Chemotherapy Induced Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Infection
- Associated Therapies
- -
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
- Conditions
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionDrug: CisplatinProcedure: Computed TomographyDrug: Doxorubicin HydrochlorideDrug: Gemcitabine HydrochlorideBiological: DurvalumabProcedure: Magnetic Resonance ImagingDrug: MethotrexateBiological: PegfilgrastimProcedure: Therapeutic Conventional SurgeryDrug: Vinblastine Sulfate
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 249
- Registration Number
- NCT04628767
- Locations
- 🇺🇸
Kingman Regional Medical Center, Kingman, Arizona, United States
🇺🇸Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN
- Conditions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 654
- Registration Number
- NCT04460079
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2
- Conditions
- Interventions
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- BeyondSpring Pharmaceuticals Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT04345900
- Locations
- 🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
🇺🇸Emad Ibrahim, MD, Inc., Redlands, California, United States
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Harbin, China
Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
- Conditions
- Ann Arbor Stage II Diffuse Large B-Cell LymphomaAnn Arbor Stage II Follicular LymphomaAnn Arbor Stage II Marginal Zone LymphomaAnn Arbor Stage III Diffuse Large B-Cell LymphomaAnn Arbor Stage III Follicular LymphomaAnn Arbor Stage III Marginal Zone LymphomaAnn Arbor Stage IV Diffuse Large B-Cell LymphomaAnn Arbor Stage IV Follicular LymphomaAnn Arbor Stage IV Marginal Zone LymphomaDiffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2020-03-27
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 50
- Registration Number
- NCT04323956
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Plinabulin iv Solution in Prevention of TAC Induced Neutropenia
- Conditions
- Interventions
- First Posted Date
- 2020-01-14
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- BeyondSpring Pharmaceuticals Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT04227990
- Locations
- 🇨🇳
Cancer Center of Guangzhou Medical University Breast Oncology, Guangzhou, Guangzhou, China
🇨🇳Fourth Hospital of Hebei Medical University Breast cancer department, Shijiazhuang, Hebei, China
🇨🇳China-Japan Union Hospital of Jilin University Tumor department of Hematology, Changchun, Jilin, China
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 102
- Registration Number
- NCT04174742
- Locations
- 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT04023669
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
KRN125 for Mobilization of Hematopoietic Stem Cells
- Conditions
- Interventions
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT03993639
- Locations
- 🇯🇵
Hokkaido University Hospital, Sapporo, Hokkaido, Japan
Split-Dose R-CHOP for Older Adults With DLBCL
- Conditions
- Interventions
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 26
- Registration Number
- NCT03943901
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
- Conditions
- Lymphocyte-Rich Classic Hodgkin LymphomaAnn Arbor Stage III Hodgkin LymphomaClassic Hodgkin LymphomaAnn Arbor Stage III Nodular Sclerosis Classic Hodgkin LymphomaAnn Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin LymphomaAnn Arbor Stage IV Mixed Cellularity Classic Hodgkin LymphomaAnn Arbor Stage IV Nodular Sclerosis Classic Hodgkin LymphomaAnn Arbor Stage III Lymphocyte-Depleted Classic Hodgkin LymphomaAnn Arbor Stage III Mixed Cellularity Classic Hodgkin LymphomaAnn Arbor Stage IV Hodgkin Lymphoma
- Interventions
- Procedure: Biospecimen CollectionDrug: Brentuximab VedotinProcedure: Computed TomographyDrug: DacarbazineDrug: Doxorubicin HydrochlorideBiological: FilgrastimProcedure: Magnetic Resonance ImagingBiological: NivolumabBiological: PegfilgrastimProcedure: Positron Emission TomographyOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Radiation TherapyDrug: Vinblastine Sulfate
- First Posted Date
- 2019-04-09
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 995
- Registration Number
- NCT03907488
- Locations
- 🇺🇸
Corewell Health Beaumont Troy Hospital, Troy, Michigan, United States
🇺🇸Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States
🇺🇸Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.